Visiongain has published a new report entitled the Artificial Intelligence (AI) in Drug Discovery 2022-2032. It includes profiles of Artificial Intelligence (AI) in Drug Discovery and Forecasts Market Segment by Offering, (AI Software, AI Services) Market Segment by Technology, (Deep Learning, Supervised Learning, Reinforcement Learning, Unsupervised Learning, Other Technology) Market Segment by Applications, (Oncology, Infectious Diseases, Neurological Disorders, Metabolic Diseases, Cardiovascular Diseases, Other Applications) Market Segment by Type, (Target Identification, Molecule Screening, Drug Design and Drug Optimization, Preclinical and Clinical Testing) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) Profiles of Leading Companies, Region and Country.
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.
In a Pharmacological Screen, AI Has a Stronger Prediction Power for Defining Relevant Interactions
AI makes use of the most recent developments in biology and computation to create cutting-edge drug discovery algorithms. AI has the potential to level the playing field in drug research, with to rapid increases in computing capacity and lower processing costs. In a pharmacological screen, AI has a stronger prediction power for defining relevant interactions. As a result, by carefully choosing the assay parameters in question, the risk of false positives can be decreased. Most crucially, AI has the ability to shift drug screening from the bench to a virtual lab, where results can be produced more quickly and intriguing targets can be prioritised without requiring extensive experimental input or personnel hours.
Download Exclusive Sample of Report @
Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032
How has COVID-19 had a significant negative impact on the Artificial Intelligence (AI) in Drug Discovery Market?
The COVID-19 pandemic presented a significant challenge to the pharmaceutical and bioanalytical communities in the creation of vaccines and therapies, as well as ongoing drug development activities. Existing procedures were tested to cope with reduced personnel at facilities and increased workloads for COVID-19-related study assistance, which included preclinical testing, clinical trial initiation, bioanalysis, and interactions with regulatory bodies, all in ultra-short timelines. Creative reimagining of procedures and the removal of barriers some of which had previously been regarded immovable were major factors in the project's success. Pharmaceutical firms working on antiviral medicines or vaccines have to deal with pandemic-related problems and alter their strategies in order to continue enrolling patients in existing clinical studies and developing new treatments and cures. The remainder of this essay focuses on bioanalysis and drug development issues and lessons learned.
How this Report Will Benefit you?
Visiongains 483 page report provides 270 tables and 264 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global artificial intelligence (AI) in drug discovery market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Artificial Intelligence (AI) in Drug Discovery. Get the financial analysis of the overall market and different segments including type, technology, application, offering and capture higher market share. We believe that high opportunity remains in this fast-growing artificial intelligence (AI) in drug discovery market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the current market drivers?
AI Utilizes the Latest Advances in Biology and Computing to Develop State-of-the-Art Algorithms for Drug Discovery
With the introduction of artificial intelligence (AI) and machine learning, the pharmaceutical business is undergoing a significant transformation. While many see this new technology as a potential threat, it could actually be the solution to our persistent prescription shortages. Indeed, AI has already proven to be useful in several aspects of drug discovery and development, from assisting scientists in finding new potential treatments to forecasting which pharmaceuticals will fail clinical trials. There's no doubt that these technologies will have a huge impact on the future of medicine as more pharma companies adopt them.
Thanks to AI, the Cost and Timelines of Developing a New Treatment Will Be Rewritten
The cost of discovering a new medicine is estimated to be in the billions of dollars. A huge percentage of the money invested on the nine out of ten proposed new therapy discoveries that fail somewhere between clinical trial phase I and regulatory approval goes down the drain. Surprisingly, few in the industry doubt the value of doing things differently. Many prominent pharma companies believe that the answer is within grasp when assisted by cutting-edge technology. Using the supercomputer IBM Watson, Pfizer uses machine learning (ML) or deep learning (DL) and breakthroughs to develop immuno-oncology medications.
Get Detailed TOC @
Artificial Intelligence (AI) in Drug Discovery Market Report 2022-2032
Where are the market opportunities?
A New Wave of Drug Discovery is Setting the Ideal for the World
Small-molecule drug discovery can benefit from AI in four ways: new biology, improved or original chemistry, higher success rates, and faster and cheaper discovery processes. Many issues and limits in traditional R&D can be addressed with this technique. Each tool provides drug research teams with new insights and, in some circumstances, can completely transform long-standing operations. Understanding and distinguishing between use cases is crucial because these technologies are applicable to a number of discovery scenarios and biological targets.
AI Has Received a Lot of Attention in the Pharmaceutical Business for Medication Discovery and Development
Within the pharmaceutical industry, there has been considerable focus on AI for drug discovery and development. The "AI for Drug Discovery" business includes research organisations, AI innovators both early-stage and well-funded biotech companies, and multinational pharma giants. Though artificial intelligence (AI) has only recently gained traction in the industry, computational methods to drug development particularly in chemistry and biology have a long history that predates electronic computing.
Competitive Landscape
The major players operating in the artificial intelligence (AI) in drug discovery market are Atomwise, Benevolent AI, Berg Health, Bioage, Biosymetrics, Cloud Pharmaceuticals, Cyclica, Deep Genomics, DeepMind, Envisagenics, Euretos, Exscientia, GNS Healthcare, IBM Corporation, Insilico Medicine, These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
Avoid missing out by staying informed order our report now.
Find more Visiongain research reports on Pharma sector click on the following links:
Do you have any custom requirements we can help you with?Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:dev.visavadia@visiongain.com
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10 year forecasts, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicatedmarket research reportsmeans that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:Dev VisavadiaPR at Visiongain Reports LimitedTel: + 44 0207 336 6100Email: dev.visavadia@visiongain.com
Read the original:
- Researchers create innovative verification techniques to increase security in artificial intelligence and image processing - European Research Council - April 29th, 2024 [April 29th, 2024]
- Who in Europe is investing the most in artificial intelligence? - Euronews - April 29th, 2024 [April 29th, 2024]
- 4 Artificial Intelligence (AI) Stocks Members of Congress Can't Stop Buying (and Nvidia Isn't 1 of Them!) - The Motley Fool - April 29th, 2024 [April 29th, 2024]
- The Standard Names Porter Orr Second Vice President of Artificial Intelligence Strategy and Development - NRToday.com - April 29th, 2024 [April 29th, 2024]
- Meet Nvidia CEO Jensen Huang, the man behind the $2 trillion company powering today's artificial intelligence - CBS News - April 29th, 2024 [April 29th, 2024]
- This Warren Buffett Dividend King Stock Just Invested $1.1 Billion Into Artificial Intelligence (AI) - The Motley Fool - April 29th, 2024 [April 29th, 2024]
- Joe Rogan Reveals What Could Be 'Game Over for the Human Race' - Newsweek - April 29th, 2024 [April 29th, 2024]
- LegalTech Artificial Intelligence Market to Soar to $6.4 Billion by 2028: Global Long-term Forecast to 2033 - Strategic ... - Yahoo Finance UK - April 29th, 2024 [April 29th, 2024]
- Artificial Intelligence Tokens Stumble Again! Is The AI Hype Over? - Coinpedia Fintech News - April 29th, 2024 [April 29th, 2024]
- CISA unveils guidelines for AI and critical infrastructure - FedScoop - April 29th, 2024 [April 29th, 2024]
- IBM's Webinar: Cybersecurity In The Era Of Artificial Intelligence Keynotes - AiThority - April 29th, 2024 [April 29th, 2024]
- Being and becoming a good doctor in the age of artificial intelligence - Firstpost - April 29th, 2024 [April 29th, 2024]
- Pope to take part in G7 summit in June to talk Artificial Intelligence - Crux Now - April 29th, 2024 [April 29th, 2024]
- Pope Francis to attend G7 summit to speak on artificial intelligence - Catholic News Agency - April 29th, 2024 [April 29th, 2024]
- 1 Unstoppable Artificial Intelligence (AI) Stock to Buy and Hold Forever - Yahoo Finance - April 29th, 2024 [April 29th, 2024]
- Pope to bring his call for ethical artificial intelligence to G7 summit in June in southern Italy - The Associated Press - April 29th, 2024 [April 29th, 2024]
- Elon Musk Called Tesla an Artificial Intelligence (AI) Robotics Company. Does That Make It a Buy? - The Motley Fool - April 29th, 2024 [April 29th, 2024]
- Emulating neurodegeneration and aging in artificial intelligence systems - Tech Xplore - April 29th, 2024 [April 29th, 2024]
- Pope Francis to participate in G7 session on AI - Vatican News - English - April 29th, 2024 [April 29th, 2024]
- A Once-in-a-Generation Investment Opportunity: 1 Bill Ackman Artificial Intelligence (AI) Stock to Buy Hand Over Fist ... - Yahoo Finance - April 29th, 2024 [April 29th, 2024]
- Tesla Stock Investors Cheer Progress on Its Artificial Intelligence (AI) Future - Yahoo Finance - April 29th, 2024 [April 29th, 2024]
- In Race to Build A.I., Tech Plans a Big Plumbing Upgrade - The New York Times - April 29th, 2024 [April 29th, 2024]
- A Baltimore-area teacher is accused of using AI to make his boss appear racist - NPR - April 29th, 2024 [April 29th, 2024]
- 3 Top Artificial Intelligence (AI) Stocks That Billionaires Jim Simons, Ray Dalio, and Israel Englander Are Buying - The Motley Fool - April 29th, 2024 [April 29th, 2024]
- The iPad Pro can give us a big surprise with its artificial intelligence chips. - Softonic EN - April 29th, 2024 [April 29th, 2024]
- This Artificial Intelligence (AI) Stock Could Soar 70%, According to Wall Street. Time to Buy? - Yahoo Finance - April 29th, 2024 [April 29th, 2024]
- Billionaire Bill Ackman Owns 8 Stocks -- and This Hypergrowth Artificial Intelligence (AI) Stock Isn't One of Them - The Motley Fool - April 29th, 2024 [April 29th, 2024]
- Artificial Intelligence Has Come for Our...Beauty Pageants? - Glamour - April 29th, 2024 [April 29th, 2024]
- 3 Stocks to Grab Now to Ride the Artificial Intelligence Chip Boom to Riches - InvestorPlace - April 29th, 2024 [April 29th, 2024]
- Is ASML's Big Sell-off a Warning Sign to Artificial Intelligence (AI) Investors? - The Motley Fool - April 29th, 2024 [April 29th, 2024]
- 3 Artificial Intelligence (AI) Stocks to Buy With $1,150 and Hold for Decades - Yahoo Finance - March 22nd, 2024 [March 22nd, 2024]
- This combines the power of artificial intelligence with human insights - finews.com - March 22nd, 2024 [March 22nd, 2024]
- Cohere Targets $5 Billion Valuation for ChatGPT Rival - PYMNTS.com - March 22nd, 2024 [March 22nd, 2024]
- IMF: Artificial Intelligence (AI) Will Transform 40% of Jobs. Can Investors Capitalize? - Yahoo Finance - March 22nd, 2024 [March 22nd, 2024]
- Cathie Wood Is Selling These 2 Artificial Intelligence (AI) Stocks. Should You? - Yahoo Finance - March 22nd, 2024 [March 22nd, 2024]
- iShares Robotics and Artificial Intelligence Multisector ETF (NYSEARCA:IRBO) Shares Acquired by Creative Financial ... - Defense World - March 22nd, 2024 [March 22nd, 2024]
- Inaugural Plenary Meeting of States Endorsing the Political Declaration on Responsible Military Use of Artificial ... - Department of State - March 22nd, 2024 [March 22nd, 2024]
- AMD Fell Today -- Is This a Chance to Buy the Artificial Intelligence (AI) Stock? - Yahoo Finance - March 22nd, 2024 [March 22nd, 2024]
- Artificial Intelligence (AI) Stocks Are Red-Hot, but Here's 1 to Avoid (for Now) - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- A Once-in-a-Generation Investment Opportunity: 1 Artificial Intelligence (AI) Growth Stock to Buy and Hold Forever - Yahoo Finance - March 22nd, 2024 [March 22nd, 2024]
- 2 Artificial Intelligence (AI) Stocks That Could Go Parabolic - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- Artificial intelligence will radically improve health care, but only if managed carefully - The Hill - March 22nd, 2024 [March 22nd, 2024]
- Tennessee Makes A.I. an Outlaw to Protect Its Country Music and More - The New York Times - March 22nd, 2024 [March 22nd, 2024]
- When Using Artificial Intelligence In Pharma R&D, Start With Identifying Problem To Solve - HBW Insight - March 22nd, 2024 [March 22nd, 2024]
- Why Super Micro Computer, Advanced Micro Devices, and Other Artificial Intelligence (AI) Stocks Tumbled on Tuesday - Yahoo Finance - March 22nd, 2024 [March 22nd, 2024]
- 3 Billionaires Are Selling Artificial Intelligence (AI) Stock Nvidia and Buying These 10 AI Stocks Instead - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- Nvidia Just Bought 5 Artificial Intelligence (AI) Stocks. These 2 Stand Out the Most. - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- UN adopts first global artificial intelligence resolution - ARMENPRESS - March 22nd, 2024 [March 22nd, 2024]
- This New Artificial Intelligence (AI) Chip Is a Massive Game Changer for Nvidia Stock - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- Nvidia Led the First Phase of Artificial Intelligence (AI), but These 2 Growth Stocks Will Lead the Next Phases ... - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- Meet Wall Street's Newest Stock-Split Stock, Along With the Artificial Intelligence (AI) Stock Likeliest to Follow in Its ... - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- Amid Rumors of a Deal With Rivian, Apple Acquired This Artificial Intelligence (AI) Start-Up Instead - Yahoo Finance - March 22nd, 2024 [March 22nd, 2024]
- UN adopts first global artificial intelligence resolution - CGTN - March 22nd, 2024 [March 22nd, 2024]
- 1 No-Brainer Artificial Intelligence (AI) Stock to Buy With $25 and Hold for 10 Years - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- 2 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - The Motley Fool - March 22nd, 2024 [March 22nd, 2024]
- Is Intel the Best Artificial Intelligence (AI) Semiconductor Stock to Buy Before It Skyrockets? - The Motley Fool - February 20th, 2024 [February 20th, 2024]
- The greater social implications of artificial intelligence - New Day NW - KING5.com - February 20th, 2024 [February 20th, 2024]
- AI comes to the world of beauty as eyelash robot uses artificial intelligence to place fake lashes - Fox News - February 20th, 2024 [February 20th, 2024]
- Beyer Appointed To Bipartisan Task Force On Artificial Intelligence - Falls Church News Press - February 20th, 2024 [February 20th, 2024]
- Why Did Nvidia Invest in These 5 Artificial Intelligence (AI) Stocks? Should You Buy Them, Too? - The Motley Fool - February 20th, 2024 [February 20th, 2024]
- Three key themes on artificial intelligence - Research Information - February 20th, 2024 [February 20th, 2024]
- How Artificial Intelligence is transforming consumerism - WFLA - February 20th, 2024 [February 20th, 2024]
- SAP names Philipp Herzig as chief artificial intelligence officer - CIO - February 20th, 2024 [February 20th, 2024]
- Unleashing the Power of Artificial Intelligence: Transforming Web-Based Applications for Enhanced Efficiency and User ... - Financialbuzz.com - February 20th, 2024 [February 20th, 2024]
- Koch Industries continues to accelerate its artificial intelligence initiative - The Business Journals - February 20th, 2024 [February 20th, 2024]
- Forget Nvidia: These 3 Artificial Intelligence (AI) Stocks Can Be the Next Stock-Split Stocks - The Motley Fool - February 20th, 2024 [February 20th, 2024]
- Artificial Intelligence for small business focus of upcoming JWCC Lunch and Learn on Feb. 28 Muddy River News - Muddy River News - February 20th, 2024 [February 20th, 2024]
- Opponents Highlight the Environmental Impact of Artificial Intelligence - News-Press Now - February 20th, 2024 [February 20th, 2024]
- Generative AI's environmental costs are soaring and mostly secret - Nature.com - February 20th, 2024 [February 20th, 2024]
- Chapter Summary: Genesis of Artificial Intelligence and a Scientific Revolution: 1950-1979 - EIN News - February 20th, 2024 [February 20th, 2024]
- What would Thomas Aquinas make of Artificial Intelligence? - ACI Africa - February 20th, 2024 [February 20th, 2024]
- ChatGPT Predicted Bitcoin Price Will "Skyrocket" - Cryptonews - February 20th, 2024 [February 20th, 2024]
- Worried About an Artificial Intelligence (AI) Stock Bubble? Consider This Billionaire Investor's Advice. - Yahoo Finance - February 20th, 2024 [February 20th, 2024]
- This Super Artificial Intelligence (AI) Stock Could Be at the Beginning of a Terrific Bull Run - Yahoo Finance - February 20th, 2024 [February 20th, 2024]
- 5 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - Yahoo Finance - February 20th, 2024 [February 20th, 2024]
- Will AI replace Colorado teachers? Here's what experts say. - The Colorado Sun - February 20th, 2024 [February 20th, 2024]
- Nvidia Could Be About to Counter a Big Artificial Intelligence (AI) Threat With This Move - Yahoo Finance - February 20th, 2024 [February 20th, 2024]
- The Healthiest U.S. Pharma Companies: Ranked by RealRate's Impressive Artificial Intelligence - Medium - February 20th, 2024 [February 20th, 2024]
- Down 84%, Is This Artificial Intelligence (AI) Stock a Buy After an Earnings Pop? - The Motley Fool - February 20th, 2024 [February 20th, 2024]
- 'AI for Humans' may be the most entertaining way to learn about artificial intelligence - Fast Company - February 20th, 2024 [February 20th, 2024]